Accession Number: | 0001209191-22-035879 |
Date: | 2022-06-08 |
Issuer: | LYELL IMMUNOPHARMA, INC. (LYEL) |
Original Submission Date: |
RIEFLIN WILLIAM JL
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO, CA 94080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
OPTION (RIGHT TO BUY) | 5.31 | 2022-06-08 | deemed execution date | A | 65,000 (a) | 2032-06-07 | common stock 65,000 | $5.31 | 65,000 | direct |
ID | footnote |
---|---|
f1 | the option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following june 8, 2022 (or the date immediately prior to such date if the reporting person's service as a director ends at such annual meeting due to the reporting person's failure to be reelectedor the reporting person not standing for re-election); or (b) the first anniversary of june 8, 2022, subject to the reporting personproviding continuous service through such date. |